2026-07-22T05:26:28Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184832024-11-28T14:47:53Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982

00925njm 22002777a 4500 dc Arias de la Rosa, Iván author Escudero-Contreras, Alejandro author Ruiz-Ponce, Miriam author Román-Rodríguez, Cristóbal author Pérez-Sánchez, Carlos author Ábalos-Aguilera, María del Carmen author Ortega-Castro, Rafaela author Alcaide, Juan author Murri, Mora author Font, Pilar author Calvo-Gutiérrez, Jerusalem author Luque-Tevar, Maria author Patiño-Trives, Alejandra Maria author Guzmán-Ruiz, Rocío author Malagón, Maria del Mar author Tinahones, Francisco José author Collantes-Estévez, Eduardo author López-Pedrera, Chary author Barbarroja, Nuria author 2021-10-13 Disease severity, progression and response to therapy might be worse in obese rheumatoid arthritis (RA) patients, but paradoxically, obesity also might protect from radiographic joint damage. Thus, the intricate relationship between obesity and RA needs urgent clarification. The aim of this study was to assess the influence of obesity on the onset and development of RA and to determine whether arthritis could modify the adipose tissue biology and whether conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) can modulate these alterations. Two strategies were followed: (1) clinical profiling of two cohorts of RA: non-obese and obese patients; and (2) mechanistic studies carried out in both a collagen-induced arthritis (CIA) in an obese mouse model and 3T3-L1 adipocytes treated with cDMARDs (leflunomide, methotrexate, and hydroxychloroquine). In our cohort of RA patients with low-moderate disease activity, the presence of obesity was not related to a higher activity of the disease; actually, disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) was reduced in the obese RA patients. However, the induction of arthritis promoted transcriptomic changes in the adipose tissue under obesity condition in the obese CIA model. Treatment with hydroxychloroquine reduced weight and insulin resistance, accompanied by beneficial metabolic effects in the adipose tissue. These molecular changes in adipose tissue were also observed after methotrexate administration. In sum, arthritis might affect directly the inflammatory burden and metabolic alterations associated with obesity in adipose tissue. Clinicians should be cautious measuring the activity of the disease in obesity and managing the best therapeutic options for the metabolic comorbidities of these patients, where the combination of hydroxychloroquine and methotrexate should be considered to improve adipose tissue dysfunction in obese RA. 10.3389/fimmu.2021.744022 1664-3224 Frontiers in Immunology http://hdl.handle.net/10668/4179 34721412 http://hdl.handle.net/20.500.12105/18483 Rheumatoid arthritis Obesity Inflammation Adipose tissue cDMARDs Leflunomide Hydroxychloroquine Methotrexate Artritis reumatoide Obesidad Inflamación Tejido adiposo Antirreumáticos Leflunomida Hidroxicloroquina Metotrexato Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs